Want to see AAPG full AI Analyst Report?
Top Page
Ascentage Pharma Group International Unsponsored ADR
(NASDAQ:AAPG)
Select Model
Select Model
Rating:49Neutral
Price Target:
$17.00
▼(-2.07% Downside)
Action:Reiterated
Date:08/21/26
The score is held back primarily by weak financial performance (large and worsening losses plus significant cash burn) and a bearish technical setup (price below key moving averages with negative MACD). The latest earnings call improves the outlook with solid revenue growth, a defined cash runway through 2027, and meaningful clinical/regulatory progress, but it does not fully offset near-term funding and execution risks.
Positive Factors
Product-led revenue growth
Strong growth led by product sales indicates increasing commercial adoption rather than reliance solely on collaboration income. A larger recurring product base can support future investment in the pipeline and improve operating leverage as sales expand.
Negative Factors
Deepening unprofitability
Rapidly widening losses show that revenue growth has not yet translated into sustainable earnings. Continued unprofitability can constrain reinvestment flexibility and increase dependence on financing, partnerships, or successful future product launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Product-led revenue growth
Strong growth led by product sales indicates increasing commercial adoption rather than reliance solely on collaboration income. A larger recurring product base can support future investment in the pipeline and improve operating leverage as sales expand.
Read all positive factors
Ascentage Pharma Group International Unsponsored ADR (AAPG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.65B
Dividend YieldN/A
Average Volume (3M)6.10K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth69.80%
EPS Growth-12.46%
CountryUS
Employees767
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-15.60
Shares Outstanding93,404,060
10 Day Avg. Volume6,724
30 Day Avg. Volume6,096
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.33
Price to Sales (P/S)29.25
P/FCF Ratio-13.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.00Price Target Upside164.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$122.74M
Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model
Company Description
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, in...
How the Company Makes Money
null...
Ascentage Pharma Group International Unsponsored ADR Earnings Call Summary
Earnings Call Date:Aug 19, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 31, 2027
Earnings Call Sentiment Positive
Overall the call conveyed substantial positive progress: meaningful revenue growth (+29.3% YoY), solid product sales contribution ($41.6M), a strong cash balance ($279.4M) and clear clinical/regulatory momentum with multiple FDA/EMA-cleared global registrational trials and promising efficacy/safety data for core assets (lisaftoclax and olverembatinib). The company reinforced commercialization capabilities with senior hires and a Takeda option for global rights to olverembatinib. Offsetting risks include rapidly rising R&D and commercial spending (R&D +32%, S&D +64.3% YoY), limited runway visibility beyond end-2027 without further funding or partner actions, competitive pressures in key therapeutic classes, and some early-stage programs that require more data. On balance, the positives — regulatory progress, strong clinical signals, revenue growth and strategic partnerships — outweigh the near-term financial and competitive risks.Positive Updates
Revenue Growth and Product Sales
Total revenue grew to $44.5 million for 1H26, up 29.3% year-over-year on a constant exchange rate basis. Product sales were $41.6 million and comprised the majority of revenue (~93.5% of total revenue).
Negative Updates
Rising R&D Spend
Research & development expenses increased to $102.8 million in 1H26 from $73.8 million in 1H25, an increase of $29.0 million or ~32% on a constant exchange rate basis, reflecting aggressive enrollment and global trial activity.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Product Sales
Total revenue grew to $44.5 million for 1H26, up 29.3% year-over-year on a constant exchange rate basis. Product sales were $41.6 million and comprised the majority of revenue (~93.5% of total revenue).
Read all positive updates
Company Guidance
Management reaffirmed a cash runway through the end of 2027 with $279.4 million in cash as of June 30, 2026 to fund nine global registrational programs (four cleared by FDA/EMA) and seven active clinical assets (two approved); H1 revenue was $44.5M (up ~29% YoY from $32.6M) with product sales of $41.6M, while H1 operating spend included R&D $102.8M (vs $73.8M, +$29M/+32%), selling & distribution $33.4M (vs $19.2M, +$14.2M/+64.3%) and admin $17.5M (vs $13.9M). Enrollment updates: GLORA-2 is complete, GLORA-3 is near complete, and GLORA-4 plus POLARIS‑1/2 are expected to finish enrollment late this year/early next year (POLARIS‑2 total ~333 patients with a 48‑patient Part B), putting the company on track to pursue as many as three NDA filings in the second half of next year; commercial execution goals include expanding the China commercial team from ~300 toward ~400 to cover ~2,000 hospitals.Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 633.01M | 558.48M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 516.31M | 426.75M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.30B | -1.10B | -237.63M | -743.61M | -786.97M | -798.34M |
| Net Income | -1.45B | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | ||||||
| Total Assets | 3.24B | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 2.47B | 1.24B | 1.07B | 1.48B | 1.71B |
| Total Debt | 2.10B | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.68B | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 556.58M | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | -1.40B | -1.20B | -135.65M | -782.92M | -890.88M | -1.04B |
| Operating Cash Flow | -1.38B | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | 617.65M | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 1.70B | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Unsponsored ADR Technical Analysis
Negative
17.36
Price Trends
37.24
Negative
38.97
Negative
Market Momentum
-1.44
Positive
34.89
Neutral
11.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 17.36 is below the 20-day moving average (MA) of 34.27, below the 50-day MA of 37.24, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.44 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.
Ascentage Pharma Group International Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $2.09B | -14.45 | -72.07% | ― | -69.78% | -106.07% | |
57 Neutral | $1.98B | -12.26 | -28.66% | ― | -28.56% | 10.25% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $1.18B | -3.93 | -207.18% | ― | -7.27% | -48.89% | |
51 Neutral | $1.33B | -9.53 | -35.35% | ― | ― | 28.64% | |
49 Neutral | $1.65B | -7.57 | -153.85% | ― | 69.80% | -12.46% | |
48 Neutral | $1.86B | -200.39 | -2.35% | ― | 20.19% | ― |
* General Sector Average
AAPG
Ascentage Pharma Group International Unsponsored ADR
17.62
-23.43
-57.08%
XNCR
Xencor
26.61
18.20
216.41%
KURA
Kura Oncology
13.25
5.11
62.78%
ZYME
Zymeworks
29.19
14.00
92.17%
ORIC
Oric Pharmaceuticals
12.86
2.36
22.48%
IMCR
Immunocore Holdings
36.13
-0.51
-1.39%
Ascentage Pharma Group International Unsponsored ADR Corporate Events
Ascentage Pharma Corrects Timing for August 19, 2026 Interim Results Webcast
Aug 13, 2026
On August 5, 2026, Ascentage Pharma Group International issued a corrected announcement stating it will report unaudited six-month 2026 interim results and provide a corporate update via webcast at 7:00 a.m. Eastern Daylight Time and 7:00 p.m. Hon...
Ascentage Pharma CEO Dajun Yang Ranked Among Top Small-Molecule Leaders in 2026 Power List
Jul 27, 2026
On July 26, 2026, Ascentage Pharma announced that its co-founder, Chairman and CEO Dr. Dajun Yang was ranked No. 3 in the Small Molecules category of The Medicine Maker Power List 2026, an annual global ranking of 60 leaders across drug discovery,...
Ascentage Pharma Sets Up US$200 Million Nasdaq ATM Offering Following SEC Shelf Filing
Jul 20, 2026
On July 20, 2026, Ascentage Pharma Group International announced that it had filed an automatic shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission as a well-known seasoned issuer, enabling future offerings of...
Ascentage Pharma Corrects AGM Date Underpinning Equity Incentive Mandate
Jul 14, 2026
Ascentage Pharma Group International, a Hong Kong–listed biopharmaceutical company incorporated in the Cayman Islands and based in Suzhou, China, develops innovative cancer and related therapies while operating under a board structure that i...
Ascentage Pharma Showcases First Pediatric Alrizomadlin Data at ASCO 2026
Jun 1, 2026
Ascentage Pharma reported on May 31, 2026 that it presented its first dataset for alrizomadlin (APG-115), an orally administered, highly selective MDM2-p53 inhibitor, in pediatric solid tumors at the 62nd American Society of Clinical Oncology Annu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.